Invasive fungal infections kill more than one million people in hospitals each year worldwide. Opportunistic infections caused by common fungal strains including Candida and Aspergillus can be life-threatening to people with compromised immune systems, such as those who are undergoing chemotherapy as a cancer treatment or those with organ transplants, immune disorders, diabetes and advanced HIV infection.
The treatment options for invasive fungal infections (IFIs) are very limited. There are mainly three classes of commonly used antifungals, and only one has the option to be administered orally. This limited number of options is concerning, particularly if we consider that many of these infections require several weeks of antifungal treatment (i.e., intravenous formulation for the entire treatment duration is not ideal). The only class with oral alternatives, the azoles, has higher potential for significant drug-to-drug interactions and has been particularly affected by the growing antifungal resistance.
SCYNEXIS is researching the efficacy of ibrexafungerp in fighting invasive fungal infections. Two of our key global open-label Phase 3 studies of oral ibrexafungerp for the treatment of invasive fungal infections are focused in this area.
Open-label study to evaluate the efficacy and safety of ibrexafungerp in patients with refractory or intolerant fungal diseases.
Open-label study to evaluate the efficacy and safety of ibrexafungerp in patients with Candidiasis caused by Candida auris.
Global Phase 3 study to evaluate ibrexafungerp as an oral step-down treatment for invasive candidiasis (IC) in the hospital setting.